TC
MRTX

TFS Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TFS Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,389
Closed -$64K – 799
2017
Q1 		$64K Sell
12,389
-10,437
-46% -$57.2K 0.02% 614
2016
Q4 		$108K Buy
22,826
+12,213
+115% +$66.4K 0.03% 628
2016
Q3 		$70K Buy
+10,613
New +$56.5K 0.02% 693
2015
Q4 		– Sell
-30,436
Closed -$1.05M – 935
2015
Q3 		$1.05M Buy
+30,436
New +$920K 0.1% 324
2014
Q1 		– Sell
-17,510
Closed -$291K – 1626
2013
Q4 		$291K Buy
+17,510
New +$299K 0.01% 1114

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

TFS Capital's MRTX Position: Q2 2017 in Review

TFS Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2017, closing a stake of 12,389 shares — an estimated $64K sold.

TFS Capital first reported a position in MRTX in Q4 2013 and held it in 5 quarters. The position peaked at $1.05M in Q3 2015. 51 funds tracked by Wall St. Rank hold MRTX as of Q2 2017.

  • TFS Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 12,389 Mirati Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $64K.
  • TFS Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
  • TFS Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $1.05M in Q3 2015.
  • 51 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.